Review



human prostate carcinoma cell line du145  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC human prostate carcinoma cell line du145
    Human Prostate Carcinoma Cell Line Du145, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 8591 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostatic+carcinoma+cell+lines/DU+145/pm42126812-145-14-30
    Average 99 stars, based on 8591 article reviews
    human prostate carcinoma cell line du145 - by Bioz Stars, 2026-10
    99/100 stars

    Images

    Related Articles

    Derivative Assay:

    Article Title: Neuropeptides bombesin and calcitonin inhibit apoptosis-related elemental changes in prostate carcinoma cell lines.
    Article Snippet: .. Two prostatic carcinoma cell lines were used: PC-3, a p53 deficient prostate cell line derived from a bone metastasis (Nuclear Iberia, Madrid, Spain), and Du 145 (American Type Culture Collection, Rockville, MD), which was derived from a brain metastasis from a prostatic carcinoma. .. Cells were grown in Dulbecco modified essential medium (ICN Biomedicals, Aurora, OH) supplemented with 10% fetal bovine serum (FBS; Boehringer, Heidelberg, Germany), 4% penicillin-streptomycin (Biochrom, Berlin, Germany), and 0.4% gentamycin (Gibco, Paisley, Scotland) under standard conditions in a water-saturated atmosphere of 5% CO2 until the experiment was started.

    Cell Culture:

    Article Title: Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model.
    Article Snippet: High circulating insulin-like growth factor-1 (IGF-1) levels increase the risk of prostate cancer.. However, whether circulating IGF-1 levels directly aggravate prostate cancer remains elusive.. In this study, we crossed a transgenic prostate adenocarcinoma mouse model, Hi-Myc mice, with a liver-specific IGF-1 transgenic mouse model (HIT) to increase their circulating IGF-1 levels to investigate the impact of the elevated circulating IGF-1 on prostate cancer development in vivo.

    Article Title: Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate-specific glandular kallikrein.
    Article Snippet: All inserts were verified by sequencing, using the T7 Sequencing Kit (Pharmacia Biotech, Uppsala, Sweden). .. Cell culture and transient transfection assays The human prostatic carcinoma cell lines (LNCaP and PC-3) and the monkey kidney cell line CV-1 were obtained from American Type Culture Collection (Rockville, MD). ..

    Transfection:

    Article Title: Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate-specific glandular kallikrein.
    Article Snippet: All inserts were verified by sequencing, using the T7 Sequencing Kit (Pharmacia Biotech, Uppsala, Sweden). .. Cell culture and transient transfection assays The human prostatic carcinoma cell lines (LNCaP and PC-3) and the monkey kidney cell line CV-1 were obtained from American Type Culture Collection (Rockville, MD). ..



    Similar Products

    human prostate carcinoma cell line du145  (ATCC)
    99
    ATCC human prostate carcinoma cell line du145
    Human Prostate Carcinoma Cell Line Du145, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostatic+carcinoma+cell+lines/DU+145/pm42126812-145-14-30
    Average 99 stars, based on 1 article reviews
    human prostate carcinoma cell line du145 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    rm 1 mouse prostate carcinoma cell line  (ATCC)
    96
    ATCC rm 1 mouse prostate carcinoma cell line
    Rm 1 Mouse Prostate Carcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostatic+carcinoma+cell+lines/RM-1/10__1016_slash_j__tmed__2026__100014-162-9-41
    Average 96 stars, based on 1 article reviews
    rm 1 mouse prostate carcinoma cell line - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    human prostate carcinoma cell lines lncap  (DSMZ)
    95
    DSMZ human prostate carcinoma cell lines lncap
    Human Prostate Carcinoma Cell Lines Lncap, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostatic+carcinoma+cell+lines/LNCAP/10__1158_slash_1535___7163__mct___25___1274-109-6-23
    Average 95 stars, based on 1 article reviews
    human prostate carcinoma cell lines lncap - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    prostate carcinoma cell line du 145  (ATCC)
    99
    ATCC prostate carcinoma cell line du 145
    Prostate Carcinoma Cell Line Du 145, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostatic+carcinoma+cell+lines/DU+145/pm41708845-127-18-23
    Average 99 stars, based on 1 article reviews
    prostate carcinoma cell line du 145 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    human prostate carcinoma cell line 22rv1  (ATCC)
    99
    ATCC human prostate carcinoma cell line 22rv1
    Human Prostate Carcinoma Cell Line 22rv1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostatic+carcinoma+cell+lines/22Rv1/pm40545998-315-14-20
    Average 99 stars, based on 1 article reviews
    human prostate carcinoma cell line 22rv1 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    prostate carcinoma 3 cell line pc 3 castration resistant  (ATCC)
    99
    ATCC prostate carcinoma 3 cell line pc 3 castration resistant
    Prostate Carcinoma 3 Cell Line Pc 3 Castration Resistant, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostatic+carcinoma+cell+lines/PC-3/10__3390_slash_cancers18010026-87-42-53
    Average 99 stars, based on 1 article reviews
    prostate carcinoma 3 cell line pc 3 castration resistant - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    androgen independent prostate carcinoma du 145 cell line  (ATCC)
    99
    ATCC androgen independent prostate carcinoma du 145 cell line
    Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and <t>DU</t> <t>145</t> cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).
    Androgen Independent Prostate Carcinoma Du 145 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostatic+carcinoma+cell+lines/DU+145/pmc12808719-133-17-29
    Average 99 stars, based on 1 article reviews
    androgen independent prostate carcinoma du 145 cell line - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    androgen independent prostate carcinoma du 145 cell line 249  (ATCC)
    99
    ATCC androgen independent prostate carcinoma du 145 cell line 249
    Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and <t>DU</t> <t>145</t> cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).
    Androgen Independent Prostate Carcinoma Du 145 Cell Line 249, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostatic+carcinoma+cell+lines/DU+145/pm41372423-141-26-39
    Average 99 stars, based on 1 article reviews
    androgen independent prostate carcinoma du 145 cell line 249 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and DU 145 cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: Characterisation of prostate cancer-derived extracellular vesicles. EVs post differential ultracentrifugation were characterised using nanoparticle tracking analysis (NTA), immunoblotting analysis, and scanning electron microscopy (SEM). a ). Particle concentration and size of which three replicates of each sample were analysed by NTA independently. Data analysed by one-way ANOVA test and presented as mean bars (n = 3) ± SEM, the significant p-value is reported; * indicates p < 0.05, ** indicates p < 0.01. n.s. = not significant. b ) Representative graphs of prostate cancer EVs distribution from NTA software. c )Immunoblotting analysis of EVs from PC-3, LNCaP and DU 145 cells and cell lysates. Detection of EVs associated positive markers, syntenin, CD63, and negative marker calnexin. SEM images of d ) PC-3 EVs, e ) LNCaP EVs and f) DU 145 EVs with a range of 90 nm to 130 nm (magnification 62000x).

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Derivative Assay, Western Blot, Electron Microscopy, Concentration Assay, Software, Marker

    Effect of PC-3 and LNCaP EVs on monocyte populations. PBMCs were treated with PC-3 EVs, LNCaP EVs, DU 145 EVs and t-NEPC LNCaP EVs for 24 h. a ) Comparison of % CD14 + CD16 + rare monocytes from 10 healthy volunteers treated with EVs derived from PC-3, LNCaP and DU 145. b ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3, LNCaP and DU 145 in respect to the untreated samples (CTRL). c ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3 compared to t-NEPC LNCaP treated cells. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** p < 0.0001; *** indicates p < 0.001; n.s. = not significant.

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: Effect of PC-3 and LNCaP EVs on monocyte populations. PBMCs were treated with PC-3 EVs, LNCaP EVs, DU 145 EVs and t-NEPC LNCaP EVs for 24 h. a ) Comparison of % CD14 + CD16 + rare monocytes from 10 healthy volunteers treated with EVs derived from PC-3, LNCaP and DU 145. b ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3, LNCaP and DU 145 in respect to the untreated samples (CTRL). c ) Comparison of % CD14 + CD16 + rare monocytes treated with EVs derived from PC-3 compared to t-NEPC LNCaP treated cells. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** p < 0.0001; *** indicates p < 0.001; n.s. = not significant.

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Comparison, Derivative Assay

    PC-3-EVs effects on innate lymphoid and NK cells compared to LNCaP-EVs. Effect of prostate cancer EVs on innate immune cells. a ) The percentage of CD4 + HLA-DR + after treatment with EVs derived from PC-3 and DU 145 compared to LNCaP treatment. b ) The percentage of CD8 + HLA-DR + treated with EVs derived from PC-3 and DU 145 in comparison to LNCaP treatment. c ) Comparison of the ratio of CD4 + HLA-DR + regarding the CD4 + . d ) Comparison of ratio of CD8 + HLA-DR + in regard to the CD8 + . Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; * indicates p < 0.05; n.s. = not significant.

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: PC-3-EVs effects on innate lymphoid and NK cells compared to LNCaP-EVs. Effect of prostate cancer EVs on innate immune cells. a ) The percentage of CD4 + HLA-DR + after treatment with EVs derived from PC-3 and DU 145 compared to LNCaP treatment. b ) The percentage of CD8 + HLA-DR + treated with EVs derived from PC-3 and DU 145 in comparison to LNCaP treatment. c ) Comparison of the ratio of CD4 + HLA-DR + regarding the CD4 + . d ) Comparison of ratio of CD8 + HLA-DR + in regard to the CD8 + . Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; * indicates p < 0.05; n.s. = not significant.

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Derivative Assay, Comparison

    Release of cytokines by immune cells after treatment with prostate cancer EVs. Seven pro- and anti-inflammatory cytokines were evaluated from the conditioned medium of PBMCs from 10 healthy donors and samples treated with PC-3-EVs, LNCaP-EVs and DU 145 EVs for 24h. a ) Level of IL-6 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. b ) Level of MIP-1α between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. c ) Level of IL-7 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. d ) Level of IFN-α2 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. e ) Level of IL-10 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. f ) Level of MCP-1 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. g ) Level of G-CSF between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** indicates p < 0.0001; ***indicates p < 0.001; ** indicates p < 0.01; *indicates p < 0.05.

    Journal: Scientific Reports

    Article Title: Immune profiling identifies the contribution of extracellular vesicles to immune modulation and progression in prostate cancer

    doi: 10.1038/s41598-025-31838-w

    Figure Lengend Snippet: Release of cytokines by immune cells after treatment with prostate cancer EVs. Seven pro- and anti-inflammatory cytokines were evaluated from the conditioned medium of PBMCs from 10 healthy donors and samples treated with PC-3-EVs, LNCaP-EVs and DU 145 EVs for 24h. a ) Level of IL-6 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. b ) Level of MIP-1α between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. c ) Level of IL-7 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. d ) Level of IFN-α2 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. e ) Level of IL-10 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. f ) Level of MCP-1 between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. g ) Level of G-CSF between PBMCs treated with PC-3 EVs and DU 145 EVs compared to LNCaP EVs. Data analysed by one-way ANOVA and presented as mean bars (n = 10) ± SEM, the significant p -value is reported; **** indicates p < 0.0001; ***indicates p < 0.001; ** indicates p < 0.01; *indicates p < 0.05.

    Article Snippet: The androgen-dependent LNCaP metastatic prostate carcinoma cell line (CRL-1740), androgen-independent prostate carcinoma PC-3 cell line (CRL-1435) and androgen-independent prostate carcinoma DU 145 cell line (HTB-81) were purchased from the American Type Culture Collection (ATCC).

    Techniques: